A jury found that Eli Lilly breached an implied covenant of good faith and fair dealing in a collaboration covering Nektar Therapeutics’ lead immuno-oncology candidate rezpegaldesleukin. Nektar was awarded $90 million plus interest, a result investors initially treated as a win even as the payout fell short of Nektar’s $1 billion damages request.